Among these markers, the role of cyclin D1 and p16 expression as prognostic markers for CDK4/6 inhibitors is still controversial, even in similar groups of patients with ER+/HER2- breast cancer [24,25], and requires further evaluation in preclinical and clinical models. The gene discussed is ERBB2; the disease is breast cancer.